RNA Outsourcing Resources

  1. How To Build Effective Clinical Trial Oversight And Leadership 7/14/2025

    In a collaborative outsourcing model, the sponsor maintains direct contact with functional leads, eliminating communication gaps and enabling faster, better-informed decision-making.

  2. Is Your Biologics CDMO Transparent? 12/12/2025

    Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.

  3. Is Not Using A CDMO Slowing Down Your Process Development? 4/27/2020

    Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful but also improve your chances of getting to market sooner.

  4. Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs 8/14/2023

    Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.

  5. Contract Design And Development Vs. In-House: Finding The Best Fit 11/18/2024

    Outsourcing medical device R&D to Contract Development Organizations (CDOs) aids innovation, scales resources, and overcomes constraints. Strategic evaluation ensures successful partnerships.

  6. Screening T7 Polymerases To Optimize xRNA Yield And Quality 10/31/2025

    Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

  7. Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO 9/2/2025

    In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

  8. Exploring The Spatial Distribution Of mRNA-Lipid Nanoparticles Using MALDI MSI 4/23/2025

    Learn how leveraging high-resolution MALDI-MSI can advance the development of lipid nanoparticle-based therapies, uncovering spatial biodistribution, pharmacokinetics, and organ-specific variability.

  9. Improvement Of Self-Amplifying RNA Quality And Potency With IVT Optimization 2/4/2026

    Explore our study on optimizing In-Vitro Transcription (IVT) conditions for self-amplifying RNAs to achieve high yields, low residual dsRNA, and improved potency, and learn how these advancements can enhance RNA-based therapies.

  10. CDMO Or No CDMO... That Is The Question 12/12/2025

    Success depends on assessing internal capabilities and knowing when outsourcing can accelerate timelines. Learn how strategic decisions reduce risk, avoid costly delays, and keep your organization competitive.